BCM
TOVX icon

Bridgeway Capital Management’s Theriva Biologics TOVX Stock Holding History

Bridgeway Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,141
Closed -$12.3K – 1376
2023
Q4 		$12.3K Hold
1,141
– – ﹤0.01% 1349
2023
Q3 		$15.4K Hold
1,141
– – ﹤0.01% 1348
2023
Q2 		$28.5K Hold
1,141
– – ﹤0.01% 1354
2023
Q1 		$19.9K Hold
1,141
– – ﹤0.01% 1356
2022
Q4 		$13K Hold
1,141
– – ﹤0.01% 1355
2022
Q3 		$28K Buy
+1,141
New +$43.8K ﹤0.01% 1379
2022
Q1 		– Sell
-297
Closed -$20K – 1355
2021
Q4 		$20K Hold
297
– – ﹤0.01% 1254
2021
Q3 		$34K Hold
297
– – ﹤0.01% 1278
2021
Q2 		$45K Sell
297
-140
-32% -$20.1K ﹤0.01% 1320
2021
Q1 		$75K Hold
437
– – ﹤0.01% 1339
2020
Q4 		$42K Hold
437
– – ﹤0.01% 1295
2020
Q3 		$52K Hold
437
– – ﹤0.01% 1297
2020
Q2 		$56K Buy
+437
New +$41.6K ﹤0.01% 1272
2017
Q2 		– Sell
-41
Closed -$228K – 1472
2017
Q1 		$228K Sell
41
-9
-18% -$62.8K ﹤0.01% 1251
2016
Q4 		$336K Sell
50
-1
-2% -$10.3K ﹤0.01% 1205
2016
Q3 		$769K Sell
51
-15
-23% -$224K 0.01% 907
2016
Q2 		$1.04M Hold
66
– – 0.02% 763
2016
Q1 		$1.37M Buy
66
+40
+154% +$601K 0.02% 638
2015
Q4 		$520K Hold
26
– – 0.01% 1044
2015
Q3 		$516K Buy
26
+20
+333% +$492K 0.01% 1010
2015
Q2 		$143K Buy
+6
New +$120K ﹤0.01% 1399
2014
Q4 		– Sell
-5
Closed -$71K – 1508
2014
Q3 		$71K Hold
5
– – ﹤0.01% 1445
2014
Q2 		$69K Hold
5
– – ﹤0.01% 1413
2014
Q1 		$103K Hold
5
– – ﹤0.01% 1383
2013
Q4 		$61K Sell
5
-4
-44% -$50.5K ﹤0.01% 1373
2013
Q3 		$134K Hold
9
– – ﹤0.01% 1355
2013
Q2 		$138K Buy
+9
New +$123K 0.01% 1322

Other funds holding TOVX

SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bridgeway Capital Management's TOVX Position: Q1 2024 in Review

Bridgeway Capital Management sold out of Theriva Biologics (TOVX) in Q1 2024, closing a stake of 1,141 shares — an estimated $12.3K sold.

Bridgeway Capital Management first reported a position in TOVX in Q2 2013 and held it in 27 quarters. The position peaked at $1.37M in Q1 2016. 20 funds tracked by Wall St. Rank hold TOVX as of Q1 2024.

  • Bridgeway Capital Management reported no remaining Theriva Biologics position as of Q1 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,141 Theriva Biologics shares in Q1 2024, an estimated $12.3K.
  • Bridgeway Capital Management first reported a position in Theriva Biologics in Q2 2013 and held it in 27 quarters.
  • Bridgeway Capital Management's Theriva Biologics position peaked at $1.37M in Q1 2016.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.